Last reviewed · How we verify
TNG462
At a glance
| Generic name | TNG462 |
|---|---|
| Sponsor | Tango Therapeutics, Inc. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- S095035 as a Single Agent and in Combination in Adult Participants With Advanced or Metastatic Solid Tumors With Deletion of MTAP (PHASE1, PHASE2)
- Study to Evaluate the Safety, Tolerability & Efficacy of TNG462 in Combination in PDAC & NSCLC Patients (PHASE1, PHASE2)
- Safety and Tolerability of TNG462 in Patients With MTAP-deleted Solid Tumors (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- TNG462 CI brief — competitive landscape report
- TNG462 updates RSS · CI watch RSS
- Tango Therapeutics, Inc. portfolio CI